Gemcitabine controlled release (Sustained Therapeutics)

吉西他滨控释制剂 (Sustained Therapeutics)

Report date: 2024/07/04 18:03:13

Base Information

Drug NameGemcitabine controlled release (Sustained Therapeutics)
Drug Alias NameGemcitabine sustained release (Sustained Therapeutics)ST-02
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionRibonucleotide reductase inhibitorsDNA inhibitors
TargetsRibonucleotide reductaseDNA
Therapy Area/IndicationsHeart FailureUrethral NeoplasmsCarcinoma, Transitional Cell +[4] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryCanada
CombinationsNo
Global Highest StatusPhase 3 Clinical
Highest Status in ChinaN/A
Originator CompaniesSustained Therapeutics Inc
China Registration ClassN/A

Develop Information

Active CompaniesSustained Therapeutics IncThe University Of British Columbia
Inactive CompaniesN/A
Active IndicationsHeart FailureUrethral NeoplasmsCarcinoma, Transitional Cell +[4] 
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A